ClinicalTrials.Veeva

Menu

Effect of Antibiotics on Gut Microbiome and Plasma Metabolome

F

Finnish Institute for Health and Welfare

Status and phase

Completed
Phase 4

Conditions

Microbial Colonization

Treatments

Drug: Vancomycin
Drug: Azithromycin
Drug: Amoxicillin

Study type

Interventional

Funder types

Other

Identifiers

NCT03273296
1341/6.00.00/2017

Details and patient eligibility

About

In recent years it has been observed that the gut microbiome can produce metabolites into systemic circulation and thus have important health effects even outside the gastrointestinal system. These metabolites may play a role in the pathogenesis of common public health problems such as diabetes, obesity and cardiovascular disorders. Modern techniques of mass spectrometry-based metabolomics from peripheral blood and gut metagenome sequencing now enable detailed examination of these processes. Using samples from the FINRISK 2002 cohort, collected by the National Institute for Health and Welfare, we are currently determining the gut microbiome and plasma metabolome from > 7000 participants with 15 years of follow-up for various health outcomes. This is one of the largest materials of its kind world-wide. The design does not, however, allow us to draw causal conclusions on the roles of gut bacteria in the composition of plasma metabolome. To enable conclusions which go beyond statistical associations, we now propose an extension to the FINRISK 2002 study, where we alter the gut bacteriome with a short course of antibiotics and then examine whether a change in plasma metabolomics profile will follow. At the same time the trial will give important novel information about the effects of commonly used antibiotics on gut bacteriome and on general health.

Enrollment

39 patients

Sex

All

Ages

40 to 74 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Prior participation in the FINRISK 2002 survey and current residence in Helsinki metropolitan area.
  • Age range 40-74 years among men and 50-74 years among women.

Exclusion criteria

  • Known allergy to any antibiotic
  • A course of antibiotic during the past year
  • Acute infection
  • Any major illness (history of myocardial infarction, stroke, diabetes, liver or kidney disease, cancer, psychiatric disease). Uncomplicated hypertension is allowed. Likewise, statin treatment and women's hormone replacement therapy are allowed.

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

39 participants in 3 patient groups

Amoxicillin
Active Comparator group
Treatment:
Drug: Amoxicillin
Azithromycin
Active Comparator group
Treatment:
Drug: Azithromycin
Vancomycin
Active Comparator group
Treatment:
Drug: Vancomycin

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems